Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 May;64(5):1500-2.
doi: 10.2337/db14-1871.

Ghrelin: a new incretin enhancer therapy?

Vincent G DeMarco  1 , James R Sowers  2
Affiliations
Comment

Ghrelin: a new incretin enhancer therapy?

Vincent G DeMarco et al. Diabetes. 2015 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: Proposed mechanism to explain a novel role for ghrelin in the regulation of oral glucose-stimulated GLP-1 secretion preprandial release of ghrelin that acts directly on ghrelin receptors located on enteroendocrine L-cells. This “priming” effect of ghrelin on nutrient-stimulated GLP-1 secretion requires signaling through the MAPK pathway. B: Obese mice pretreated with exogenous ghrelin exhibit enhanced GLP-1 secretion and normal glucose tolerance.
See this image and copyright information in PMC

Comment on

References

    1. Freemantle N. Commentary: what can we learn from the continuing regulatory focus on the thiazolidinediones? BMJ 2010;341:c4812. - PubMed
    1. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24–32 - PMC - PubMed
    1. Burcelin R, Gourdy P, Dalle S. GLP-1-based strategies: a physiological analysis of differential mode of action. Physiology (Bethesda) 2014;29:108–121 - PubMed
    1. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301–307 - PMC - PubMed
    1. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46–52 - PubMed

Publication types